<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03286205</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT03286205</nct_id>
  </id_info>
  <brief_title>A Randomized Study to Compare the Dosing Schedule of INFeD in Anemic Patients.</brief_title>
  <official_title>A Randomized Study to Compare the Dosing Schedule of INFeD in Anemic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sutter Gould Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sutter Gould Medical Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish which dosing schedule of INfed (Iron dextrose) is
      superior for the treatment of iron deficient anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to establish which dosing schedule of INfed (Iron dextrose) is
      superior for the treatment of iron deficient anemia. The two dosing regimens under review are
      a low dose weekly or a larger dose given every three weeks. The primary research hypothesis
      is that a superior dosing regimen exists for INfed and can be shown by a 2gm/dl increase in
      HgB. The secondary research hypothesis is that INfed can be given at high dose without an
      increase in AE and/or SAEs frequency.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2015</start_date>
  <completion_date type="Anticipated">April 14, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 14, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>superior dosing regimen exists for INfed</measure>
    <time_frame>3 years</time_frame>
    <description>shown by a 2gm/dl increase in HgB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High Dose Effect</measure>
    <time_frame>3 years</time_frame>
    <description>INfed can be given at high dose without an increase in AE and/or SAEs frequency</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Anemia, Iron Deficiency</condition>
  <arm_group>
    <arm_group_label>Weekly Dosage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>weekly dose of 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 week dosage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>every 3 week dosage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV iron</intervention_name>
    <description>IV iron infusion based on weekly or every 3 week dosage.</description>
    <arm_group_label>Weekly Dosage</arm_group_label>
    <arm_group_label>3 week dosage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients over the age of 18 years old.

          2. Being treated by a Sutter Health Physician.

          3. Hemoglobin of &lt; 10mg/dl for Men and Women

          4. Ferritin &lt;/= 10ng/ml

          5. Patients in whom oral administration is unsatisfactory or impossible.

        Exclusion Criteria:

          1. Patients with a history of receiving iron or other hematinic in the preceding 3
             months, oral iron is allowable.

          2. Anemia due to acute blood loss; menorrhagia is allowed.

          3. Patients with a current illness known to interact with iron status.

          4. Patients unwilling to consent to required blood draws.

          5. Patients who are viewed as unable to complete treatment, based on PI recommendation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Adkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen Moorman, BA</last_name>
    <phone>+1(209)521-6097</phone>
    <phone_ext>3282</phone_ext>
    <email>MoormaK@sutterhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sutter Gould Medical Foundation</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Moorman, BA</last_name>
      <phone>209-521-6097</phone>
      <email>MoormaK@sutterhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2017</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sutter Gould Medical Foundation</investigator_affiliation>
    <investigator_full_name>David Adkins</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

